GLP-1 Vitamins & Nutrient Support

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications slow gastric emptying and reduce appetite, potentially lowering overall food intake and altering nutrient absorption patterns. Research suggests users may benefit from targeted vitamin screening and supplementation, though individual needs vary significantly based on baseline nutritional status, medication dose, and duration of use.

Understanding your personal nutritional risk profile—informed by baseline biomarkers and genetic predispositions affecting metabolism—helps frame a more precise conversation with your healthcare provider about supplementation strategy. This precision-wellness approach moves beyond generic recommendations toward individualized nutrient support.

How GLP-1 Medications Affect Nutrient Status

GLP-1 agonists reduce appetite and slow stomach emptying, leading to decreased caloric and nutrient intake in many users. Additionally, lower food volume may reduce intake of nutrient-dense foods, and altered gastric transit time can affect absorption efficiency of certain vitamins and minerals.

Clinical data from GLP-1 trials show users experience weight loss averaging 5-15% over 6-12 months. This rapid weight reduction, combined with reduced eating frequency, increases risk for micronutrient gaps, particularly in vitamin B12, folate, iron, and calcium.

Key Nutrients at Risk: Evidence-Based Overview

Several vitamins and minerals warrant particular attention during GLP-1 therapy. Understanding the mechanism of risk for each helps inform targeted screening and supplementation decisions with your provider.

Nutrient	Risk Factor with GLP-1	Screening Recommendation	Typical Dose if Supplementing
Vitamin B12	Reduced food intake; slowed gastric emptying may reduce intrinsic factor interaction	Baseline and annual serum B12 or holotranscobalamin	1000–2000 mcg monthly injection or 1000–2000 mcg daily oral
Folate (B9)	Lower intake from reduced vegetable/grain consumption	Baseline and 6-month serum folate	400–800 mcg daily oral
Iron	Reduced meat/legume intake; altered gastric pH affects absorption	Baseline hemoglobin, ferritin, TIBC	15–27 mg daily (dose/form depends on baseline status)
Calcium	Lower dairy/fortified food intake; possibly altered absorption	Baseline serum calcium, vitamin D	1000–1200 mg daily divided with food

Biomarker Screening Before and During GLP-1 Therapy

Baseline micronutrient screening before starting GLP-1 therapy provides a clinical anchor point for monitoring. Key markers include serum B12, folate, iron panel, vitamin D, and calcium. Establishing these baselines helps distinguish pre-existing deficiency from GLP-1-related shifts.

Follow-up screening at 3–6 months and annually thereafter helps identify emerging deficiencies early. If you experience persistent fatigue, hair loss, numbness, or bone density concerns during GLP-1 use, request targeted micronutrient labs to guide intervention strategy with your provider.

Personalization Through Genetic and Metabolic Context

Genetic variations in nutrient metabolism and absorption pathways can influence how efficiently your body processes vitamins and minerals. For example, variants in folate metabolism genes (MTHFR, MTHFD) or iron regulatory genes (HFE) may predispose certain individuals to faster depletion or absorption challenges during caloric restriction.

PlexusDx's Precision Peptide Genetic Test reveals predispositions in metabolic and peptide signaling pathways that can help inform nutrient screening priorities. Combined with baseline biomarker data, genetic context may help your provider tailor supplementation timing, dose, and form—supporting a more informed discussion about your individual nutritional needs during GLP-1 therapy.

Supplementation Timing, Form, and Safety Considerations

Timing matters: take fat-soluble vitamins (A, D, E, K) with meals containing fat to maximize absorption. B vitamins and minerals like iron and calcium absorb better on an empty stomach or with acidic beverages, but spacing doses 2+ hours apart from medications reduces interaction risk. Injectable B12 bypasses absorption variability entirely.

Choose supplement forms based on your absorption efficiency. Methylated folate and cyanocobalamin injections bypass intestinal absorption, while ferrous salts and citrate forms of calcium show better bioavailability than their oxide counterparts. Always discuss timing, dose, and form with your healthcare provider to avoid interactions with your GLP-1 therapy or other medications.

Who Should Prioritize Micronutrient Screening on GLP-1 Therapy

Certain populations face higher nutritional risk during GLP-1 use: those with pre-existing absorption disorders (celiac, inflammatory bowel disease), vegetarians/vegans with limited natural B12 sources, individuals with a prior history of nutrient deficiency, and those over 50 years old with naturally declining stomach acid and intrinsic factor production.

If you fall into any of these groups, baseline micronutrient labs and follow-up screening every 3–6 months support proactive management. Early identification of emerging deficiencies allows for timely supplementation and dosing adjustments, reducing long-term risk of anemia, bone loss, or neurological complications.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in metabolic and nutrient-handling pathways—such as folate metabolism (MTHFR), iron regulation (HFE), and glucose-insulin signaling genes—that may help provide context for your individualized nutrient risk profile. These predispositions should be interpreted alongside baseline biomarker data and clinical history by a qualified healthcare provider to guide targeted screening and supplementation strategy.

The genetic test does not predict your exact response to GLP-1 therapy or guarantee specific nutrient outcomes. Instead, it reveals genetic predispositions in metabolic and peptide-signaling pathways that may influence how efficiently you absorb and utilize certain vitamins and minerals. This information can support a more personalized conversation with your provider about which micronutrient markers warrant closer monitoring during treatment.

Integrating genetic predisposition data with baseline biomarker screening, symptom history, and dietary assessment creates a more complete picture of your nutritional risk during GLP-1 therapy. This evidence-informed approach helps your healthcare provider make targeted supplementation recommendations rather than relying on generic one-size-fits-all guidance.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose GLP-1 Protocol is $129/mo flat. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which nutrients does this article single out as most at risk during GLP-1 therapy?

It highlights four: vitamin B12, folate, iron, and calcium. The stated reasons differ by nutrient. B12 risk comes from reduced food intake and slowed gastric emptying, folate from lower vegetable and grain consumption, iron from reduced meat and legume intake plus altered gastric pH, and calcium from lower dairy and fortified food intake with possibly altered absorption. Each has its own screening marker listed alongside it.

Why would slowed gastric emptying affect vitamin B12 specifically?

The article ties B12 risk to both lower food volume and slowed gastric transit, which it says may reduce intrinsic factor interaction. It also flags that people over 50 already have naturally declining stomach acid and intrinsic factor production, which stacks on top of the medication effect. Suggested screening is a baseline and annual serum B12 or holotranscobalamin so a gap is caught before symptoms appear.

How often does the article suggest micronutrient labs be repeated once treatment is underway?

It recommends baseline screening before starting GLP-1 therapy, follow-up at three to six months, and annually thereafter. The point of the baseline is to create a clinical anchor so a pre-existing deficiency can be told apart from a shift caused by the medication. For higher-risk groups, the article suggests staying on the three-to-six-month cadence rather than moving straight to yearly checks.

Which symptoms should prompt me to ask for targeted micronutrient labs?

The article names persistent fatigue, hair loss, numbness, and bone density concerns as signals worth investigating with targeted micronutrient labs rather than waiting for the next scheduled draw. Its reasoning is that catching an emerging deficiency early allows intervention before it progresses to anemia, bone loss, or neurological complications. Bring the specific symptom and its timeline to your provider so the right panel gets ordered.

Why does the article say the form of a supplement matters as much as the nutrient?

Because different forms clear different absorption hurdles. It notes that methylated folate and cyanocobalamin injections bypass intestinal absorption entirely, and that ferrous salts and citrate forms of calcium show better bioavailability than their oxide counterparts. It also distinguishes fat-soluble vitamins, which depend on dietary fat for uptake, from B vitamins and minerals. Form, timing, and dose are all flagged as decisions to make with your provider.

Who is at higher-than-average risk of nutrient gaps on a GLP-1?

The article names four groups: people with pre-existing absorption disorders such as celiac disease or inflammatory bowel disease, vegetarians and vegans with limited natural B12 sources, anyone with a prior history of nutrient deficiency, and adults over 50 with declining stomach acid and intrinsic factor production. For these groups it recommends baseline labs plus follow-up screening every three to six months rather than annual checks.

Related Reading

• Temporary Glp 1 Provider While Prior Authorization Pending Plexusdx
• Glp 1 Medications
• Glp 1 Support Diet Plant Based
• Glp 1 Support Diet

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.